These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31436857)

  • 1. Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review.
    Henrique ICB; de Mendonça Lima T; de Melo DO; Aguiar PM
    J Clin Pharm Ther; 2020 Feb; 45(1):1-15. PubMed ID: 31436857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
    Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM
    Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?
    Aguiar PM; Lima TM; Storpirtis S
    J Clin Pharm Ther; 2016 Apr; 41(2):189-97. PubMed ID: 27009796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
    Achilla E; McCrone P
    Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France].
    Gozlan G; Lecardeur L; Monfort AS; Doz M; Ortiz I; Larroumets P; Lafuma A
    Encephale; 2018 Dec; 44(6):496-503. PubMed ID: 30482480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.
    Rajagopalan K; Trueman D; Crowe L; Squirrell D; Loebel A
    Pharmacoeconomics; 2016 Jul; 34(7):709-21. PubMed ID: 27067724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
    J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
    Zhao J; Jiang K; Li Q; Zhang Y; Cheng Y; Lin Z; Xuan J
    J Med Econ; 2019 May; 22(5):439-446. PubMed ID: 30732487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.
    Lin Z; Xuan J
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):549-557. PubMed ID: 32757968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis.
    Lin L; Zhao YJ; Zhou HJ; Khoo AL; Teng M; Soh LB; Lim BP; Sim K
    Int Clin Psychopharmacol; 2016 Mar; 31(2):84-92. PubMed ID: 26619182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.
    Fleeman N; McLeod C; Bagust A; Beale S; Boland A; Dundar Y; Jorgensen A; Payne K; Pirmohamed M; Pushpakom S; Walley T; de Warren-Penny P; Dickson R
    Health Technol Assess; 2010 Jan; 14(3):1-157, iii. PubMed ID: 20031087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of paliperidone extended release in Spain.
    Treur M; Baca E; Bobes J; Cañas F; Salvador L; Gonzalez B; Heeg B
    J Med Econ; 2012; 15 Suppl 1():26-34. PubMed ID: 23016569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
    Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
    Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the real-world effectiveness and economic and humanistic outcomes of selected oral antipsychotics among patients with schizophrenia in the United States: Updating the evidence and gaps.
    Jeun KJ; Kamal KM; Adhikari K; Nolfi DA; Ashraf MN; Zacker C
    J Manag Care Spec Pharm; 2024 Feb; 30(2):183-199. PubMed ID: 38308625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.